Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Read original at benzingaStocks · News reference
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.28 by 3.13 percent. This is a 15.79 percent increase over earnings of $1.14 per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 11:27 AM
- Checked
- Aug 5, 2026, 11:27 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Royalty Pharma Announces $100M Agreement To Acquire Zealand Pharma's Rusfertide Economics, Including 1% Global Royalty; $50M At Closing, $50M On First Anniversary
Read original at benzingaJP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.
Read original at benzinga8-K filing — Royalty Pharma plc (RPRX)
Filed: 2026-08-05 AccNo: 0001802768-26-000014 Size: 480 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar